{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:42:47Z","timestamp":1792017767839,"version":"4.4.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1097\/01.coc.0000158829.63542.2c","type":"journal-article","created":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T14:41:37Z","timestamp":1122907297000},"page":"334-339","source":"Crossref","is-referenced-by-count":7,"title":["A Phase II Study of Intravenous Exatecan Administered Daily for 5 Days, Every 3 Weeks to Patients With Biliary Tract Cancers"],"prefix":"10.1097","volume":"28","author":[{"given":"Ghassan K.","family":"Abou-Alfa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric K.","family":"Rowinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda Z.","family":"Patt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary K.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Kelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos R.","family":"Becerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S Gail","family":"Eckhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevie","family":"Feit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"De Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"O'Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210128","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1053\/jhep.2001.25087","article-title":"Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.","volume":"33","author":"Patel","year":"2001","journal-title":"Hepatology"},{"key":"R2-3-20210128","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","article-title":"American Cancer Society. Cancer statistics, 2004.","volume":"54","author":"Jemal","year":"2004","journal-title":"Ca Cancer J Clin"},{"key":"R3-3-20210128","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/1097-0142(19840915)54:6<965::AID-CNCR2820540603>3.0.CO;2-X","article-title":"Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer.","volume":"54","author":"Falkson","year":"1984","journal-title":"Cancer"},{"key":"R4-3-20210128","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1023\/A:1011135014895","article-title":"A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma.","volume":"12","author":"Sanz\u2013Altamira","year":"2001","journal-title":"Ann Oncol"},{"key":"R5-3-20210128","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000011961","article-title":"Two consecutive phase II studies of 5-fluorouracil\/leucovorin\/mitomycin C and of gemcitabine in patients with advanced biliary cancer.","volume":"56","author":"Raderer","year":"1999","journal-title":"Oncology"},{"key":"R6-3-20210128","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1023\/A:1012543223020","article-title":"A phase II study of gemcitabine in gallbladder carcinoma.","volume":"12","author":"Gallardo","year":"2001","journal-title":"Ann Oncol"},{"key":"R7-3-20210128","first-page":"783","article-title":"Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas.","volume":"48","author":"Kubicka","year":"2001","journal-title":"Hepatogastroenterology"},{"key":"R8-3-20210128","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/0959-8049(95)00323-B","article-title":"Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours.","volume":"31A","author":"Ellis","year":"1995","journal-title":"Eur J Cancer"},{"key":"R9-3-20210128","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1023\/A:1008241008379","article-title":"Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin.","volume":"9","author":"Ducreux","year":"1998","journal-title":"Ann Oncol"},{"key":"R10-3-20210128","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/00000421-200304000-00015","article-title":"Gemcitabine and cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder.","volume":"26","author":"Malik","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"R11-3-20210128","first-page":"367","article-title":"A well tolerated and highly effective regimen for locally advanced and metastatic biliary tract cancers with gemcitabine and cisplatin [abstract 1473].","volume":"22","author":"Baluch","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R12-3-20210128","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/annonc\/mdh351","article-title":"Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.","volume":"15","author":"Andr\u00e9","year":"2004","journal-title":"Ann Oncol"},{"key":"R13-3-20210128","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1517\/13543784.7.4.625","article-title":"Antitumor activity of DX-8951f: a new camptothecin derivative.","volume":"7","author":"Kumazawa","year":"1998","journal-title":"Exp Opin Invest Drugs"},{"key":"R14-3-20210128","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1349-7006.1995.tb02468.x","article-title":"A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.","volume":"86","author":"Mitsui","year":"1995","journal-title":"Jap J Cancer Res"},{"key":"R15-3-20210128","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1749-6632.2000.tb07044.x","article-title":"DX-8951f: summary of phase I clinical trials.","volume":"922","author":"De Jager","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"R16-3-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials.","volume":"10","author":"Simon","year":"1989","journal-title":"Controlled Clin Trials"},{"key":"R18-3-20210128","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00944177","article-title":"Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria.","volume":"10","author":"Green","year":"1992","journal-title":"Invest New Drugs"},{"key":"R19-3-20210128","article-title":"IT2S user's guide.","author":"Collins","year":"1995"},{"key":"R20-3-20210128","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.2000.18.17.3151","article-title":"DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.","volume":"18","author":"Rowinsky","year":"2000","journal-title":"J Clin Oncol"},{"key":"R21-3-20210128","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1093\/annonc\/mdf262","article-title":"Intra-arterial hepatic chemotherapy combined with continuous infusion of 5-fluorouracil in patients with metastatic cholangiocarcinoma.","volume":"13","author":"Cantore","year":"2002","journal-title":"Ann Oncol"},{"key":"R22-3-20210128","first-page":"21","article-title":"Final results of a phase II study of DX-8951f (exatecan mesylate, DX) in advanced pancreatic cancer [abstract 532].","author":"D'Adamo","year":"2001","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.coc.0000158829.63542.2c","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:56:33Z","timestamp":1785855393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000421-200508000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.coc.0000158829.63542.2c","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}